Edition:
United Kingdom

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,827.00GBp
13 Nov 2018
Change (% chg)

37.00 (+2.07%)
Prev Close
1,790.00
Open
1,795.50
Day's High
1,841.50
Day's Low
1,795.50
Volume
1,089,786
Avg. Vol
612,079
52-wk High
2,089.00
52-wk Low
814.20

Summary

Name Age Since Current Position

Said Darwazah

60 2018 Executive Chairman of the Board

Sigurdur Olafsson

49 2018 Chief Executive Officer

Mazen Darwazah

59 2014 Executive Vice Chairman of the Board, President and Chief Executive Officer of MENA and Emerging Markets

Khalid Nabilsi

2011 Chief Financial Officer

Brian Hoffman

2017 President, US Generics Division

Riad Mishlawi

2017 CEO, Injectables Division

Bryan Hotston

Chief Information Officer

Susan Ringdal

2016 Vice President - Corporate Strategy and Investor Relations

Hussein Arkhagha

2013 General Counsel

Bassam Kanaan

53 2014 Chief Strategy and Corporate Development Officer

Majda Labadi

2017 Chief Human Capital Officer

Peter Speirs

2012 Company Secretary

Ali Al-Husry

60 2005 Non-Executive Director

Jochen Gann

53 2015 Non-Executive Director

Patrick Butler

57 2014 Non-Executive Independent Director

John Castellani

67 2016 Non-Executive Independent Director

Ronald Goode

74 2006 Non-Executive Independent Director

Nina Henderson

67 2016 Non-Executive Independent Director

Pamela Kirby

65 2014 Non-Executive Independent Director

Robert Pickering

58 2014 Senior Non-Executive Independent Director

Biographies

Name Description

Said Darwazah

Mr. Said Samih Darwazah is Executive Chairman of the Board of the Company. Said has served as Chief Executive since July 2007 and Chairman since May 2014. Said has over 36 years of experience in numerous leadership roles at Hikma. Under Said’s leadership, Hikma has expanded into the US and become a leading player in injectables and the MENA region. Industrial Engineering degree from Purdue University, MBA from INSEAD.

Sigurdur Olafsson

Mr. Sigurdur Oli Olafsson is Chief Executive Officer of the Company. Siggi has a wealth of international experience in the pharmaceutical industry, having held senior roles with Actavis Pharma Inc., Pfizer Inc. and Omega Farma. Siggi served as President and CEO of Global Generic Medicines at Teva Pharmaceuticals. M.S. in Pharmacy (Cand Pharm) from the University of Iceland, Reykjavik.

Mazen Darwazah

Mr. Mazen Samih Talib Darwazah is Executive Vice Chairman of the Board, President and Chief Executive Officer of MENA and Emerging Markets of Hikma Pharmaceuticals Plc. Mazen has led and expanded the MENA region at Hikma. Since listing, he has Group level responsibility in his role as Executive Vice Chairman. Since 2014, he became responsible for the Group’s expansion into emerging markets. BA in Business Administration from the Lebanese American University, AMP from INSEAD.

Khalid Nabilsi

Mr. Khalid Nabilsi is Chief Financial Officer of Hikma Pharmaceuticals Plc. Khalid is responsible for Group finance, including reporting and capital management, and information technology. Khalid has held several financial positions during 17 years with Hikma, including VP Finance. US Certified Public Accountant. MBA from the University of Hull.

Brian Hoffman

Mr. Brian Hoffman is President, US Generics Division of the Company. Brian is responsible for all aspects of the Generics division in the US. Brian has significant strategic and operational experience from leadership roles at Hikma and prior consulting roles. BA in Business Administration from Boston University. MBA from the University of Chicago.

Riad Mishlawi

Mr. Riad Mishlawi is CEO, Injectables Division of the Company. Riad is responsible for all aspects of the Injectables division globally. Riad has significant pharmaceutical and operational experience from leadership roles at Hikma and Watson Pharmaceuticals. BSc in Engineering and a Master’s in Engineering and Management from George Washington University.

Bryan Hotston

Mr. Bryan Hotston is Chief Information Officer of the Company. Bryan has Group wide responsibility for information technology and systems enhancement. Prior to joining Hikma, Bryan held IT leadership positions with Barclays Capital and JP Morgan Cazenove, where he was a member of the Executive and Risk committees.

Susan Ringdal

Ms. Susan Ringdal is Vice President - Corporate Strategy and Investor Relations of Hikma Pharmaceuticals Plc. Susan is responsible for investor relations, corporate affairs, the executive committee and corporate strategy. Prior to joining Hikma, Susan worked for Alliance Unichem and Morgan Stanley. BA in History from Cornell University. MBA from London Business School.

Hussein Arkhagha

Mr. Hussein Arkhagha is General Counsel of Hikma Pharmaceuticals Plc. Hussein has Group level responsibility for legal, regulatory and taxation related matters. During 17 years at Hikma, Hussein has held several legal leadership roles, including heading legal in MENA, the shareholders’ department and tax. Qualified lawyer in Jordan. Master’s degree in International Business Law from the University of Manchester, under a UK Chevening Scholarship.

Bassam Kanaan

Mr. Bassam Wael Rushdi Kanaan is Chief Strategy and Corporate Development Officer of Hikma Pharmaceuticals Plc. Bassam has Group level responsibility for strategic development, acquisitions, alliances, product development, and risk. Bassam has held several executive positions during 17 years with Hikma, including Chief Financial Officer. US Certified Public Accountant and Chartered Financial Analyst. BA from Claremont McKenna. International Executive MBA from Kellogg/ Recanati Schools of Management.

Majda Labadi

Ms. Majda Labadi is Chief Human Capital Officer of the Company. Majda has Group level responsibility for human resources, including people development and structuring. Majda has held several executive positions during 32 years with Hikma, including VP Injectables and VP MENA Operations. BA from the American University of Beirut. Master’s degree from Hochschule Fur Okonomie, Germany. Advanced Management Program at INSEAD.

Peter Speirs

Mr. Peter Speirs is Company Secretary of Hikma Pharmaceuticals Plc. Peter is responsible for advising on governance, executive remuneration, and listing related matters. Peter joined Hikma as Deputy Secretary and previously held roles with Barclays and Pool Re.

Ali Al-Husry

Mr. Ali K. Al-Husry is Non-Executive Director of Hikma Pharmaceuticals Plc. Ali held various management and leadership roles within Hikma before stepping into an advisory role in 1995, when he founded Capital Bank of Jordan, focusing on commercial and investment banking. Ali served as Chief Executive of the Bank until 2007. Mechanical Engineering degree from the University of Southern California, MBA from INSEAD.

Jochen Gann

Dr. Jochen Gann is Non-Executive Director of the Company. Jochen is Global Head of Corporate Finance/M&A and Corporate Vice President at Boehringer Ingelheim GmbH. In his M&A role he leads Boehringer Ingelheim’s mergers and acquisitions activities across all businesses. Doctorate Degree in International Finance from the University of Hoheinheim. Master’s Degree in Business Administration and Science from University of Karsruhe.

Patrick Butler

Mr. Patrick (Pat) Butler is Non-Executive Independent Director of the Company. Pat was Senior Director at McKinsey & Co. During 25 years at McKinsey, he focused on strategic, financial and structuring advice to large corporations. Pat qualified in the audit and tax practice of Arthur Andersen. Chartered accountant. First-class honours degree in Commerce, postgraduate diploma in Accounting and Corporate Finance from University College Dublin.

John Castellani

Mr. John J. Castellani is Non-Executive Independent Director of the Company. John was President and Chief Executive Officer of Pharmaceutical Research and Manufacturers of America (PhRMA) and Business Roundtable. During his career John has also held senior positions with Burson-Marsteller, Tenneco, and General Electric. BSc in Biology from Union College Schenectady, New York.

Ronald Goode

Dr. Ronald L. (Ron) Goode, Ph.D., is Non-Executive Independent Director of Hikma Pharmaceuticals Plc. Ron’s executive career focused on the international pharmaceutical industry, including roles as Chief Executive, President of International Operations at Searle, Vice President of Clinical and Scientific Affairs at Pfizer, and adviser to companies in the pharmaceutical industry.

Nina Henderson

Ms. Nina Henderson is Non-Executive Independent Director of the Company. Nina was Corporate VP of Bestfoods and President of Bestfoods Grocery prior to its acquisition by Unilever. During a 30-year career with Bestfoods, and its predecessor company CPC International, she held a wide variety of Global and North American executive general management and marketing positions. Nina has served as a director of Royal Dutch Shell, AXA Financial, The Equitable Companies, DelMonte, Pactiv and Walter Energy. Honours graduate and BSc from Drexel University.

Pamela Kirby

Dr. Pamela J. Kirby, Ph.D. is Non-Executive Independent Director of the Company. Dr Kirby was Chief Executive of Quintiles Transnational Corp and held senior executive positions at F Hoffmann-La Roche and AstraZeneca. Previously, Dr Kirby chaired Scynexis, was Senior Independent Director of Informa and held nonexecutive positions with Smith & Nephew, Novo Nordisk, Curalogic, and Oscient Pharmaceuticals Corp. First-class BSc degree in Pharmacology, Clinical Pharmacology PhD from the University of London.

Robert Pickering

Mr. Robert M. Pickering is Senior Non-Executive Independent Director of Hikma Pharmaceuticals Plc. Robert became Senior Independent Director in May 2014. Robert was Chief Executive of Cazenove Group PLC and subsequently JP Morgan Cazenove until 2008. During 23 years at Cazenove and Co. he acquired extensive experience of the corporate and investment environment. Qualified solicitor with a law degree from Lincoln College, Oxford.